Clinical Trial Update: Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating solifenacin therapy for urinary symptoms in Parkinson disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Parkinson Disease

Drugs mentioned

• Solifenacin (solifenacin)
• Vesicare (solifenacin succinate)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Overactive Bladder, Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-09-24